This classification table is based on relative biological concern — a theoretical comparison of how each peptide might interact with cancer-related pathways. It does not represent measured or proven cancer risk in humans, as human data do not currently exist to quantify absolute risk.

!!! Important !!!   Peptides do not cause cancer. Some may, in theory, promote the growth of an existing or undiagnosed tumor by stimulating natural repair or hormone pathways.!!!

Understanding the Risk Labels

Label	Evidence Basis	Meaning
	No clinical or mechanistic evidence suggesting tumor promotion. Often includes approved or long-studied compounds with post-market data.	Absence of known pro-cancer activity. Indicates low theoretical concern, not proof of absolute safety.
	Limited or mixed preclinical findings; mechanisms may intersect with growth or metabolic pathways.	Represents uncertainty. Insufficient data to confirm or dismiss cancer relevance.
	Strong biological rationale or class evidence for growth stimulation (e.g., IGF-1 increase, angiogenesis, hormonal activation).	Suggests higher theoretical oncogenic potential. Indicates mechanistic concern, not measured incidence.

These categories reflect mechanistic likelihood, not statistical measures such as relative or absolute risk. Most peptides lack human epidemiologic data.

Section 1 — Not a Known Concern

Section 2 — Caution

Section 3 — Concern

These peptides are only a concern in individuals with a diagnosed or undiagnosed cancer, as they may theoretically support growth of existing tumor cells.